Literature DB >> 22236444

Genetic and molecular characterization of uveal melanoma cell lines.

K G Griewank1, X Yu, J Khalili, M M Sozen, K Stempke-Hale, C Bernatchez, S Wardell, B C Bastian, S E Woodman.   

Abstract

The recent identification of frequent activating mutations in GNAQ or GNA11 in uveal melanoma provides an opportunity to better understand the pathogenesis of this melanoma subtype and to develop rational therapeutics to target the cellular effects mediated by these mutations. Cell lines from uveal melanoma tumors are an essential tool for these types of analyses. We report the mutation status of relevant melanoma genes, expression levels of proteins of interest, and DNA fingerprinting of a panel of uveal melanoma cell lines used in the research community. Published 2012. This article is a US Government work and is in the public domain in the USA.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22236444      PMCID： PMC3288394          DOI： 10.1111/j.1755-148X.2012.00971.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN： 1755-1471            Impact factor:   4.693


  31 in total

1.  Establishment and characterization of primary and metastatic uveal melanoma cell lines.

Authors:  G P Luyten; N C Naus; C M Mooy; A Hagemeijer; J Kan-Mitchell; E Van Drunen; V Vuzevski; P T De Jong; T M Luider
Journal:  Int J Cancer       Date:  1996-05-03       Impact factor: 7.396

2.  Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway.

Authors:  Armelle Calipel; Gaelle Lefevre; Celio Pouponnot; Frédéric Mouriaux; Alain Eychène; Frédéric Mascarelli
Journal:  J Biol Chem       Date:  2003-08-12       Impact factor: 5.157

3.  Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes.

Authors:  J Kan-Mitchell; M S Mitchell; N Rao; P E Liggett
Journal:  Invest Ophthalmol Vis Sci       Date:  1989-05       Impact factor: 4.799

4.  Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis.

Authors:  Gaëlle Lefevre; Anne-Lise Glotin; Armelle Calipel; Frédéric Mouriaux; Thi Tran; Zoulika Kherrouche; Claude-Alain Maurage; Christian Auclair; Frédéric Mascarelli
Journal:  J Biol Chem       Date:  2004-05-15       Impact factor: 5.157

5.  Characterization of gangliosides in human uveal melanoma cells.

Authors:  D Soulieres; A Rousseau; J Deschenes; M Tremblay; M Tardif; G Pelletier
Journal:  Int J Cancer       Date:  1991-10-21       Impact factor: 7.396

6.  Lack of BRAF mutation in primary uveal melanoma.

Authors:  Yoram Cohen; Nitza Goldenberg-Cohen; Paola Parrella; Itay Chowers; Shannath L Merbs; Jacob Pe'er; David Sidransky
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-07       Impact factor: 4.799

7.  Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea.

Authors:  Anette Weber; Ulrich R Hengge; Doris Urbanik; Annett Markwart; Alireza Mirmohammadsaegh; Martin B Reichel; Christian Wittekind; Peter Wiedemann; Andrea Tannapfel
Journal:  Lab Invest       Date:  2003-12       Impact factor: 5.662

8.  Establishment and characterization of an uveal-melanoma cell line.

Authors:  I De Waard-Siebinga; D J Blom; M Griffioen; P I Schrier; E Hoogendoorn; G Beverstock; E H Danen; M J Jager
Journal:  Int J Cancer       Date:  1995-07-17       Impact factor: 7.396

9.  Akt-mediated cardiomyocyte survival pathways are compromised by G alpha q-induced phosphoinositide 4,5-bisphosphate depletion.

Authors:  Amy L Howes; Jane F Arthur; Tong Zhang; Shigeki Miyamoto; John W Adams; Gerald W Dorn; Elizabeth A Woodcock; Joan Heller Brown
Journal:  J Biol Chem       Date:  2003-08-04       Impact factor: 5.157

10.  Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas.

Authors:  S C Edmunds; I A Cree; F Dí Nícolantonío; J L Hungerford; J S Hurren; D P Kelsell
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640
View more
  52 in total

1.  SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity.

Authors:  Jungsun Park; Amjad H Talukder; Seon A Lim; Kwanghee Kim; Ke Pan; Brenda Melendez; Sherille D Bradley; Kyle R Jackson; Jahan S Khalili; Junmei Wang; Caitlin Creasy; Bih-Fang Pan; Scott E Woodman; Chantale Bernatchez; David Hawke; Patrick Hwu; Kyung-Mi Lee; Jason Roszik; Gregory Lizée; Cassian Yee
Journal:  Cancer Immunol Res       Date:  2017-06-19       Impact factor: 11.151

2.  miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation.

Authors:  Vijay Kumar Eedunuri; Kimal Rajapakshe; Warren Fiskus; Chuandong Geng; Sue Anne Chew; Christopher Foley; Shrijal S Shah; John Shou; Junaith S Mohamed; Cristian Coarfa; Bert W O'Malley; Nicholas Mitsiades
Journal:  Mol Endocrinol       Date:  2015-06-12

3.  Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.

Authors:  Jahan S Khalili; Xiaoxing Yu; Ji Wang; Brendan C Hayes; Michael A Davies; Gregory Lizee; Bita Esmaeli; Scott E Woodman
Journal:  Clin Cancer Res       Date:  2012-06-25       Impact factor: 12.531

4.  Melanocortin 1 Receptor-Targeted α-Particle Therapy for Metastatic Uveal Melanoma.

Authors:  Narges K Tafreshi; Christopher J Tichacek; Darpan N Pandya; Michael L Doligalski; Mikalai M Budzevich; HyunJoo Kil; Nikunj B Bhatt; Nancy D Kock; Jane L Messina; Epifanio E Ruiz; Nella C Delva; Adam Weaver; William R Gibbons; David C Boulware; Nikhil I Khushalani; Ghassan El-Haddad; Pierre L Triozzi; Eduardo G Moros; Mark L McLaughlin; Thaddeus J Wadas; David L Morse
Journal:  J Nucl Med       Date:  2019-02-07       Impact factor: 10.057

5.  Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers.

Authors:  Rebecca E Schweppe; Nikita Pozdeyev; Laura A Pike; Christopher Korch; Qiong Zhou; Sharon B Sams; Vibha Sharma; Umarani Pugazhenthi; Christopher Raeburn; Maria B Albuja-Cruz; Philip Reigan; Daniel V LaBarbera; Iñigo Landa; Jeffrey A Knauf; James A Fagin; Bryan R Haugen
Journal:  Mol Cancer Res       Date:  2019-02-07       Impact factor: 5.852

6.  Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma.

Authors:  Amanda R Moore; Emilie Ceraudo; Jessica J Sher; Youxin Guan; Alexander N Shoushtari; Matthew T Chang; Jenny Q Zhang; Edward G Walczak; Manija A Kazmi; Barry S Taylor; Thomas Huber; Ping Chi; Thomas P Sakmar; Yu Chen
Journal:  Nat Genet       Date:  2016-04-18       Impact factor: 38.330

7.  RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.

Authors:  Xu Chen; Qiuxia Wu; Philippe Depeille; Peirong Chen; Sophie Thornton; Helen Kalirai; Sarah E Coupland; Jeroen P Roose; Boris C Bastian
Journal:  Cancer Cell       Date:  2017-05-08       Impact factor: 31.743

8.  Atypical activation of the G protein Gαq by the oncogenic mutation Q209P.

Authors:  Marcin Maziarz; Anthony Leyme; Arthur Marivin; Alex Luebbers; Prachi P Patel; Zhe Chen; Stephen R Sprang; Mikel Garcia-Marcos
Journal:  J Biol Chem       Date:  2018-10-23       Impact factor: 5.157

9.  Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.

Authors:  Nabil Amirouchene-Angelozzi; Fariba Nemati; David Gentien; André Nicolas; Amaury Dumont; Guillaume Carita; Jacques Camonis; Laurence Desjardins; Nathalie Cassoux; Sophie Piperno-Neumann; Pascale Mariani; Xavier Sastre; Didier Decaudin; Sergio Roman-Roman
Journal:  Mol Oncol       Date:  2014-06-13       Impact factor: 6.603

10.  A role for Jag2 in promoting uveal melanoma dissemination and growth.

Authors:  Laura Asnaghi; James T Handa; Shannath L Merbs; J William Harbour; Charles G Eberhart
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-09       Impact factor: 4.799
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.